1235305-63-1

Basic information

• Product Name: N-(tert-butyl)-3-methylpyridin-2-amine
• Synonyms: N-(tert-butyl)-3-methylpyridin-2-amine;N-(tert-Butyl)-3-methyl-2-pyridinamine;2-Pyridinamine, N-(1,1-dimethylethyl)-3-methyl-;EOS-60902
• CAS NO: 1235305-63-1
• Molecular Formula: C₁₀H₁₆N₂
• Molecular Weight: 164
• Mol File: 1235305-63-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 261℃
• Flash Point: 112℃
• Appearance: /
• Density: 0.977
• Storage Temp.: 2-8°C
• PKA: 7.07±0.10(Predicted)
• CAS DataBase Reference: N-(tert-butyl)-3-methylpyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(tert-butyl)-3-methylpyridin-2-amine(1235305-63-1)
• EPA Substance Registry System: N-(tert-butyl)-3-methylpyridin-2-amine(1235305-63-1)

Safety Data

• Hazardous Substances Data: 1235305-63-1(Hazardous Substances Data)

Usage

General Description

N-(Tert-butyl)-3-methylpyridin-2-amine is a chemical compound with the molecular formula C10H16N2. It is a tertiary amine with a substituted pyridine ring, containing a tert-butyl group and a methyl group. N-(Tert-butyl)-3-methylpyridin-2-amine is commonly used in organic synthesis as a building block for creating various pharmaceuticals, agrochemicals, and other fine chemicals. It can also be used as a catalyst in chemical reactions or as a ligand in coordination chemistry. N-(Tert-butyl)-3-methylpyridin-2-amine may also have potential applications in medicinal chemistry and drug discovery research. Its properties and reactivity make it a versatile and valuable compound in the field of organic chemistry.

Upstream product

• 3430-17-9 2-bromo-3-picoline 
• 75-64-9 tert-butylamine 

Downstream Products

• 957130-49-3 (R)-5-amino-1,3-dihydrospiro[indene-2,3’-pyrrolo[2,3-b]pyridin]-2’(1’H)-one 
• 957118-49-9 [3H]-MK 3207 
• 1260403-57-3 (R)-1’-(tert-butyl)-5-(dibenzylamino)-1,3-dihydrospiro[indene-2,3’-pyrrolo[2,3-b]pyridin]-2’(1’H)-one 
• 1246733-24-3 methyl 1-(tert-butyl)-2-hydroxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylate 
• 1455358-36-7 C₁₃H₁₆N₂O₃ 
• 1455358-06-1 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 1374248-83-5 (S)-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,5-trifluorophenyl)piperidin-3-yl)-2’-oxo-1‘,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3‘-pyrrolo [2,3-b]pyridine]-3-carboxamide 
• 1374248-80-2 (S)-N-((3S,5S,6R)-6-methyl-2-oxo-5-(o-tolyl)-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2’-oxo-l‘,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3’-pyrrolo[2,3-b]pyridine]-3-carboxamide 
• 1375541-21-1 (S)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxylic acid 

Relevant articles and documents

Asymmetric Dieckmann Condensation towards Spirocyclic Oxindoles Catalyzed by Amino Acid-Derived Phosphonium Salts

An asymmetric Dieckmann condensation towards spirocyclic oxindoles and aza-oxindoles catalyzed by amino acid-derived phosphonium salt has been developed, which expanded the applicability of asymmetric phosphonium salt catalysis in the production of 1,3-dicarbonyl compounds. This reaction is distinguished by its mild conditions (?20 °C), low catalyst loading (3–5 mol%), and broad substrate scope (25 examples). Control experiments revealed that both the catalyst‘s phosphonium skeleton and H-bonding site were required. Product transformations and a gram scale experiment were also carried out. (Figure presented.).

HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10,Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Piperidinone carboxamide indane CGRP receptor antagonists

The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.